BofA raised the firm’s price target on Merus (MRUS) to $52 from $44 and keeps a Buy rating on the shares after the company announced a new collaboration with Gilead (GILD) for the discovery and development of novel trispecific antibodies. The firm thinks the partnership with a large biopharmaceutical company reflects confidence in the potential for the platform to expand to trispecific antibodies and further advance the early-stage pipeline, the analyst tells investors. The firm also thinks it could help Merus leverage Gilead’s commercial and development expertise in oncology.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRUS:
- 3 Best Stocks to Buy Now, 3/8/2024, According to Top Analysts
- Merus to potentially receive $56M in deal with Gilead to discover antigens
- Gilead receives option to license novel trispecific therapeutics in Merus deal
- Merus to receive $56M upfront in deal with Gilead to discover antigens
- Merus added to Conviction List at Needham
